Company: RPTX
Filing Date: 2025-04-29
Form Type: DEF 14A
Source: 0001193125-25-103764
Chunk: 20

Company: Repare Therapeutics Inc.
Filing Date: 2025-04-29
Form: DEF 14A
Chunk 20
---
 Rhoads currently serves on the boards of directors of Globus Medical Inc., QuidelOrtho Corporation (formerly Quidel Corporation) and iTeos Therapeutics Inc. She previously served on the boards of directors of Evoke Pharma, Inc., and Iridex Corporation. Ms. Rhoads received a B.S. in finance from the University of Arkansas and an M.B.A. from Harvard Business School. Our board of directors believes that Ms. Rhoads’ extensive experience as a chief financial officer of multiple publicly traded biotech and pharmaceutical companies, in addition to her experience as a member of the boards of directors of multiple publicly traded biotech and pharmaceutical companies, qualify her to serve on our board of directors.**

<div align='center'>12</div>

### INFORMATION REGARDING THE BOARD OF DIRECTORS AND CORPORATE GOVERNANCE

#### Independence of the Board of Directors
Our common shares are listed on the Nasdaq Global Select Market (“Nasdaq”). As required under Nasdaq listing standards, a majority of the members of our board of directors must qualify as “independent,” as affirmatively determined by our board of directors. Our board of directors consults with our external counsel to ensure that its determinations are consistent with relevant securities and other laws and regulations regarding the definition of “independent,” including those set forth in pertinent listing standards of Nasdaq, as in effect from time to time.

Our nominating and corporate governance committee undertook its annual review of director independence and made a recommendation to our board of directors regarding director independence. As a result of this review, our board of directors has affirmatively determined that the following seven directors are “independent” within the meaning of the applicable Nasdaq listing standards: Dr. Bonita, Mr. Civik, Dr. Kulkarni, Dr. Molineaux, Ms. Rhoads, Ms. Schafer and Dr. Stein. In addition, our board of directors has affirmatively determined that each of Todd Foley, who resigned from our board of directors in June 2024, and Briggs Morrison, who resigned from our board of directors in August 2024, was independent during the period each of Mr. Foley and Dr. Morrison served on the board during 2024. Our board of directors determined that Mr. Forte is not independent by virtue of his executive leadership role with Repare. In addition, our board of directors previously determined that Lloyd Segal, our former President and Chief Executive Officer and a member of our board of